Regenicin announces participation in Armed Forces regenerative medicine event Print
By Staff and Wire Reports   
Tuesday, 02 November 2010 05:58

Regenicin, Inc. (OTCBB:WDST) has officially announced that they will be presenting at a key event "to celebrate the newest advancements in regenerative medicine" alongide representatives of the Armed Forces Institute of Regenerative Medicine, the U.S. Department of Defense Office of Technology Transition; as well as members of Congress, U.S. Armed Forces personnel, scientists, firefighters, and surgeons on the frontlines of treating burns and wounds in the U.S.

As exclusively reported previously in this space, the company is expected to present key information and announce important developments regarding the regenerative cell therapy they recently licensed from Swiss based life science company, Lonza AG. 

The event is scheduled to take place in Walkersville, MD- a town that lies in the shadows of some of the nations most important armed forces institutions and military bases on November 9th, 2010.

According to a press release issued by the company on Tuesday morning, Regenicin will present their role in the commercialization of the therapeutic candidate, PermaDermâ„¢, a product which could help revolutionize the way wounded warriors and civilians recover from severe burns and wounds. Speaking on behalf of Regenicin will be Dr. Craig Eagle, a member of Regenicin's Board of Directors, and head of Oncology for Pfizer Worldwide.

PermaDermâ„¢ is the only tissue-engineered skin prepared from autologous (patient's own) skin cells from both the epidermal and dermal skin layers.  A small sample of the patient's skin can be expanded in the laboratory to cover a wound site that extends over 50% of the patient's body. These self-to-self skin grafts are intended to form permanent wound closure that is not rejected by the patient's immune system, a critical possibility in porcine or cadaver skin grafts used today.


"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus